INDIGO: A GLOBAL, RANDOMIZED, DOUBLE-BLINDED, PHASE III STUDY OF VORASIDENIB VERSUS PLACEBO IN PATIENTS WITH RESIDUAL OR RECURRENT GRADE 2 GLIOMA WITH AN IDH1/2 MUTATION

Authors
Category Primary study
JournalNEURO-ONCOLOGY
Year 2023
This article has no abstract
Epistemonikos ID: 0c95bea31c5ef7eb2de9076829dfe9d9d17f4e70
First added on: Dec 07, 2023